SMMT vs. ACAD, ARWR, MRUS, MOR, MLTX, JANX, FOLD, IDYA, PTCT, and XENE
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include ACADIA Pharmaceuticals (ACAD), Arrowhead Pharmaceuticals (ARWR), Merus (MRUS), MorphoSys (MOR), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), PTC Therapeutics (PTCT), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Summit Therapeutics (NASDAQ:SMMT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
ACADIA Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, meaning that its share price is 213% less volatile than the S&P 500.
ACADIA Pharmaceuticals received 588 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 73.09% of users gave ACADIA Pharmaceuticals an outperform vote while only 56.91% of users gave Summit Therapeutics an outperform vote.
ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals presently has a consensus price target of $32.13, indicating a potential upside of 88.42%. Summit Therapeutics has a consensus price target of $8.00, indicating a potential upside of 82.23%. Given Summit Therapeutics' higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Summit Therapeutics.
In the previous week, ACADIA Pharmaceuticals had 11 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for ACADIA Pharmaceuticals and 7 mentions for Summit Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.95 beat Summit Therapeutics' score of 0.05 indicating that Summit Therapeutics is being referred to more favorably in the news media.
Summit Therapeutics has a net margin of 0.00% compared to Summit Therapeutics' net margin of -8.44%. Summit Therapeutics' return on equity of -15.67% beat ACADIA Pharmaceuticals' return on equity.
96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 27.5% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 83.7% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ACADIA Pharmaceuticals beats Summit Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
